Deletion variants within the NF-κB activation domain of the LMP1 oncogene prevail in acquired immunodeficiency syndrome-related large cell lymphomas and human immunodeficiency virus-negative atypical lymphoproliferations

Blood

Volumn 87, Issue 3, 1996, Pages 876-881

  Knecht, Hans ^a   Raphaël, Martine ^b   McQuain, Cathy ^b   Rothenberger, Sylvia ^b   Pihan, German ^b   Camilleri Broët, Sophie ^b   Bachmann, Edith ^b   Kershaw, Glenn R ^b   Ryan, Shannon ^b   Kittler, Ellen L W ^b   Quesenberry, Peter J ^b   Schlaifer, Daniel ^b   Woda, Bruce A ^b   Brousset, Pierre ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PROTEIN; ONCOPROTEIN; TRANSCRIPTION FACTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BRAIN LYMPHOMA; CARBOXY TERMINAL SEQUENCE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DNA SEQUENCE; EPSTEIN BARR VIRUS; GENE ACTIVATION; GENE MUTATION; HISTOLOGY; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT TRANSFORMATION; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION;

AMINO ACID SEQUENCE; BASE SEQUENCE; BRAIN NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; CELL TRANSFORMATION, VIRAL; GENE EXPRESSION REGULATION, VIRAL; HALF-LIFE; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HIV SERONEGATIVITY; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOPROLIFERATIVE DISORDERS; MOLECULAR SEQUENCE DATA; NF-KAPPA B; POINT MUTATION; PROTEIN STRUCTURE, TERTIARY; SELECTION (GENETICS); SEQUENCE ALIGNMENT; SEQUENCE DELETION; TUMOR VIRUS INFECTIONS; VIRAL MATRIX PROTEINS;

EID: 0030021863     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.3.876.bloodjournal873876     Document Type: Article

References (35)

1. Fennewald S, van Santen V, Kieff E: Nucleotide sequence of a mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein. J Virol 51:411, 1984
2. Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS: Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet 1:320, 1991
3. Carbone A, Tirelli U, Gloghini A, Volpe R, Boiocchi M: Human immunodeficiency virus-associated systemic lymphomas may be subdivided into two main groups according to Epstein-Barr viral latent gene expression. J Clin Oncol 11:1674, 1993
4. Hamilton-Dutoit SJ, Rea D, Raphael M, Sandvej K, Delecluse HJ, Gisselbrecht G, Marelle L, van Krieken JHHM, Pallesen G: Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Blood 82:619, 1993
5. Joske DJL, Knecht H: Epstein-Barr virus in lymphomas: A review. Blood Rev 7:215, 1993
6. Knecht H, Bachmann E, Brousset P, Rothenberger S, Einsele H, Lestou VS, Delsol G. Bachmann F, Ambros PF, Odermatt BF: Mutational hot spots within the carboxy terminal region of the LMP1 oncogene of Epstein-Barr virus are frequent in lymphoproliferative disorders. Oncogene 10:523, 1995
7. Wang D, Liebowitz D, Kieff E: An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43:831, 1985
8. Fahraeus R, Rymo L, Rhim JS, Klein G: Morphological transformation of human keratinocytes expressing the LMP gene of Epstein-Barr virus. Nature 345:447, 1990
9. Dawson CW, Rickinson AB, Young LS: Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature 344:777, 1990
10. Peng M, Lundgren E: Transient expression of the Epstein-Barr virus LMP1 gene in human primary B cells induces cellular activation and DNA synthesis. Oncogene 7:1775, 1992
11. Henderson S, Rowe M. Gregory C, Croom-Carter D, Wang F, Longnecker R, Kieff E, Rickinson A: Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 65:1107, 1991
12. Wilson JB, Weinberg W, Johnson R, Yuspa S, Levine AJ: Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of Keratin 6. Cell 61:1315, 1990
13. Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E: The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 80:389, 1995
14. Mitchell T, Sugden B: Stimulation of NF-κB-mediated transcription by mutant derivatives of the latent membrane protein of Epstein-Barr virus. J Virol 69:2968, 1995
15. Huen DS, Henderson SA, Croom-Carter D, Rowe M: The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-κB and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 10:549, 1995
16. Herrero JA, Mathew P, Paya CV: LMP-1 activates NF-κB by targeting the inhibitory molecule IκBα. J Virol 69:2168, 1995
17. Knecht H, Bachmann E, Brousset P, Sandvej K, Nadal D, Bachmann F, Odermatt BF, Delsol G, Pallesen G: Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma. Blood 82:2937, 1993
18. Brousset P, Schlaifer D, Meggetto F, Bachmann E, Rothenberger S, Delsol G, Knecht H: Persistence of the same viral strain in early and late relapses of Epstein-Barr virus associated Hodgkin's disease. Blood 84:2447, 1994
19. Camilleri-Broet C, Davi F, Feuillard J, Bourgeois C, Seilhean J, Hauw J, Raphael M: High expression of latent membrane protein 1 of Epstein-Barr virus andBCL-2 oncoprotein in acquired immunodeficiency syndrome-related primary brain lymphomas. Blood 86:432, 1995
20. Brousset P, Butet V, Chittal S, Selves J, Delsol G: Comparison of In situ hybridization using different nonisotopic probes for detection of Epstein-Barr virus in nasopharyngeal carcinoma and immunohistochemical correlation with anti-latent membrane protein antibody. Lab Invest 67:457, 1992
21. Vassallo J, Brousset P, Knecht H, Lamant L, Odermatt B, Delsol G: Detection of Epstein-Barr virus in Hodgkin's disease. Applied Immunohistochem 1:213, 1993
22. Knecht H, Bachmann E, Joske DJL, Sahli R, Emery-Goodman A, Casanova JL, Zilic M, Bachmann F, Odermatt BF: Molecular analysis of the LMP (latent membrane protein) oncogene in Hodgkin's disease. Leukemia 7:580, 1993
23. Baer R, Bankier AT, Biggin MD, Deininger PL, Farrell PJ, Gibson TJ, Hatfull G, Hudson GS, Satchwell SC, Seguin C, Tuffnell PS, Barrell BG: DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 310:207, 1984
24. Sandvej K, Peh SC, Andresen BS, Pallesen G: Identification of potential hot spots in the carboxy-terminal part of the Epstein-Barr virus (EBV) BNLF-1 gene in both malignant and benign EBV-associated diseases: High frequency of a 30-bp deletion in Malaysian and Danish peripheral T-cell lymphomas. Blood 84:4053, 1994
25. Miller WE, Edwards RH, Walling DM, Raab-Traub N: Sequence variation in the Epstein-Barr virus latent membrane protein 1. J Gen Virol 75:2729, 1994
26. Knecht H, Martius F, Bachmann E, Hoffmann T, Zimmermann DR, Rothenberger S, Sandvej K, Wegmann W, Hurwitz N, Odermatt BF, Kummer H, Pallesen G. A deletion mutant of the LMP1 oncogene of Epstein-Barr virus is associated with transformation of angioimmunoblastic lymphadenopathy into B-immunoblastic lymphoma. Leukemia 9:458, 1995
27. Kingma DW, Weiss WB, Jaffe ES, Kumar S, Raffeld M: EBV LMP1 oncogene deletions: Correlations with malignancy in EBV-associated lymphoproliferative disorders. Blood 84:644a, 1994 (abstr, suppl 1)
28. Berline JW, Penaranda ME, Lennette E, Greenspan JS, Palefsky JM: Latent membrane protein 1 sequence variation in EBV strains from hairy leukoplakia, in Pagano J, Rickinson A (eds): Epstein-Barr Virus & Associated Disease. Cold Spring Harbor, NY, 1994, p 127
29. Joske DJL, Emery-Goodman A, Odermatt BF, Bachmann E, Bachmann F, Knecht H: Epstein-Barr virus burden in Hodgkin's disease is related to latent membrane protein gene expression but not to active viral replication. Blood 80:2610, 1992
30. Moorthy RK, Thorley-Lawson DA: All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP-1 are required for transformation of Rat-1 fibroblasts. J Virol 67:1638, 1993
31. Rothenberger S, Martin J, McQuain C, Bachmann E, Quesenberry P, Knecht H: Naturally occuring deletion variants within the growth transforming domain of the LMP1 oncogene of EBV influence the LMP1 oncogene expression and colony formation. Exp Hematol 23:789, 1995 (abstr)
32. Knecht H, McQuain C, Rothenberger S, Drexler H, Martin J, Bachmann E, Kittler E, Odermatt B, Quesenberry P: Expression of the LMP1 oncoprotein in the EBV negative Hodgkin's disease cell line L-428 is associated with Reed-Sternberg cell morphology. Blood 1996 (submitted)
33. Trivedi P, Hu LF, Chen F, Chritensson B, Masucci MG, Klein G, Winberg G: Epstein-Barr virus (EBV)-encoded membrane protein LMP1 from a nasopharyngeal carcinoma is non-immunogenic in a murine model system, in contrast to a B cell-derived homologue. Eur J Cancer 30A:84, 1994
34. Martin J, Sugden B: Transformation by the oncogenic latent membrane protein correlates with its rapid turnover, membrane localization, and cytoskeletal association. J Virol 65:3246, 1991
35. Sample J, Kieff EF, Kieff ED: Epstein-Barr virus types 1 and 2 have nearly identical LMP-1 transforming genes. J Gen Virol 75:2741, 1994